TLR9 and Kaposi's sarcoma: One such example is a study between TLR9, HLA class I/II alleles, and a vaccine construct against Kaposi’s sarcoma (Chauhan et al., 2019), while another study on Candida auris vaccine design reported docking between TLR5 and MHC class-II HLA DRB_0101 with scores in a similar range (Akhtar et al., 2021).